Amneal (AMRX) Reports Q3 Earnings: What Key Metrics Have to Say

For the quarter ended September 2025, Amneal Pharmaceuticals (AMRX) reported revenue of $784.51 million, up 11.7% over the same period last year. EPS came in at $0.17, compared to $0.16 in the year-ago quarter.The reported revenue represents a surprise of +1.41% over the Zacks Consensus Estimate of $773.6 million. With the consensus EPS estimate being $0.13, the EPS surprise was +30.77%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations ...